QIMR Berghofer Centre for Immunotherapy and Vaccine Development and Translational and Human Immunology Laboratory, Department of Immunology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
School of Clinical Medicine, University of Queensland, Brisbane, Queensland, Australia.
J Infect Dis. 2021 Jul 15;224(2):312-317. doi: 10.1093/infdis/jiaa750.
Cytomegalovirus (CMV) remains a significant burden in lung transplant recipients. Deficiencies in T-cell immunity posttransplant increase the risk of CMV-associated complications. However, it is not clear if underlying poor pretransplant immunity increases risk. To assess this, we recruited 39 prospective lung transplant patients and performed QuantiFERON-CMV on their peripheral blood. More than a third of prospective CMV-seropositive transplant recipients were CMV non-immune reactive (CMV-NIR) pretransplant. CMV-NIR status was associated with a significantly higher incidence of CMV reactivation posttransplant, demonstrating that dysfunctional CMV immunity in prospective lung transplant recipients is associated with an increased risk of viral reactivation posttransplant.
巨细胞病毒（CMV）仍然是肺移植受者的重大负担。移植后 T 细胞免疫缺陷会增加 CMV 相关并发症的风险。然而，尚不清楚潜在的移植前免疫功能低下是否会增加风险。为了评估这一点，我们招募了 39 名前瞻性肺移植患者，并对其外周血进行了 QuantiFERON-CMV 检测。超过三分之一的预期 CMV 阳性移植受者在移植前为 CMV 非免疫反应性（CMV-NIR）。CMV-NIR 状态与移植后 CMV 再激活的发生率显著升高相关，表明前瞻性肺移植受者的 CMV 免疫功能障碍与移植后病毒再激活的风险增加相关。
